Lupin 2023

J M Smith Corp. appoints CFO, CTO

Print Friendly, PDF & Email

SPARTANBURG, S.C. — Philip Ryan has been named as chief financial officer and Kevin Welch as chief technology officer at J M Smith Corp.

Phil Ryan_JM Smith Corp.

Philip Ryan

The pharmacy supplier and technology provider said Thursday that Ryan will also assume the role of treasurer after the retirement of James Wilson on Oct. 1.

Wilson has been with J M Smith since 1987, serving first as controller before being named treasurer and later CFO.

“These appointments are significant steps on the path towards leadership excellence and operational excellence. Both Phil and Kevin are highly respected experts in their fields,” J M Smith chairman and chief executive officer Alan Turfe said in a statement. “Their passion for our organization and their vision for moving it forward are impressive. I am looking forward to working with them in their expanded roles.”

As CFO, Ryan has direct responsibility for finance in each J M Smith business unit as well as the corporation overall. The vice presidents of finance for each business unit will report to him. He joined J M Smith in 2011 from Sealed Air Corp.

Kevin Welch_JM Smith Corp.

Kevin Welch

J M Smith noted that Ryan was a key member of the team that handled the company’s acquisitions of Radiate, Integra and Burlington Drug Co.

Welch will retain his role as president of Integra LTC Solutions in adding CTO duties for J M Smith. In the new post, he will oversee the development and implementation of new technology companywide. Welch came to J M Smith upon the acquisition of Integra, the company he founded in 1997.

“J M Smith Corp. has a long history of providing innovative technology to the market,” Welch commented. “The role of a CTO is to ensure that we are positioned to continue to have a technological edge. I am looking forward to this new challenge.”

J M Smith’s business units include Smith Drug Co., QS/1, Integral Solutions Group, RxMedic Systems, Integra LTC Solutions and Burlington Drug Co.


Comments are closed.